NCT03612726Recruiting
The Overall Survival of Patients With Unresectable HCC in Real-life
The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region
Source: ClinicalTrials.gov · Last updated 24 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 17 Jul 2018
- Start date
- 16 Jul 2018
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Humanity & Health Medical Group Limited
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT03612726
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 16 Jul 2018 to the primary completion date, 31 Dec 2025
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients not willing to participate and/or give their written informed consent.
Who the study is looking for
- Patients with a diagnosis of unresectable hepatocellular carcinoma
- Able to comprehend and provide written informed consent in accordance with institutional guidelines.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing 302 Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Humanity & Health Medical Group Limited Coordinator of this site? Confirm its status | Hong Kong | Hong Kong | Recruiting |
| Tokyo University Coordinator of this site? Confirm its status | Tokyo | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.